In its contribution to tumourigenesis the protein kinase family is overrepresented compared to other protein families [1, 2] . Mutations of kinase genes (point mutations, gene amplification, deletion, insertions and translocations) 
Jak2-V617F signal transduction
In murine bone marrow transfer models, introduction of the Jak2-V617F mutation is sufficient to induce a PV phenotype [31] [32] [33] [34] . Cytokine receptor binding is necessary for the transforming potential of the Jak2-V617F mutant [31, 35] [25, 35, 39, 40] . Jak2-V617F was also described to promote G1/S phase transition trough a redox-dependent regulation of cyclinD1 and p27 [41] . Signalling through Jak2-V617F has been described to lead to genetic instability [42] . SOCS1 and SOCS3 mRNA upregulation has recently been reported in patients with Jak2-V617F-associated myeloproliferative disorders [43, 44] . These proteins are known to down-regulate Jak activity and mediate their degradation [45] [46] [47] [48] . It was reported that Jak2-V617F may escape the direct inhibition by SOCS3 [49] . In contrast, SOCS3 was recently shown to negatively regulate Jak2-V617F activity via its kinase inhibitory region and SH2 domain and to mediate Jak2-V617F ubiquitination and degradation [50] . Despite this negative regulation, the constitutive signalling capacity of Jak2-V617F was not totally abrogated and higher levels of steady state Jak2-V617F were observed to have higher levels of constitutive signalling [50] . In patients with PV and PMF, the Jak2-V617F mutation frequently progresses to homozygosity through mitotic recombination, which is less frequently observed in patients with ET [26] and in these MPN the expression level was reported to reflect the allele load [51] . Animal studies also support the hypothesis that higher levels of Jak2-V617F lead from a thrombocytic to an erythrocytic and a fibrotic phenotype [32, 51, 52] [53, 54] . Negative regulation of Jak2-V617F by SOCS2 was also described and in the same study inactivation of the SOCS2 gene by hypermethylation was reported in Jak2-V617F positive leukaemic cell lines and in MPN patient cells [55] . The expression and potential mutation of SOCS proteins could be important clinical parameters in patients carrying constitutively active Jak2 proteins.
. Thus, mechanisms interfering with the negative regulation and degradation of activated Jaks could considerably contribute to the development and progression of MPD and Jak2-V617F-positive leukaemia by increasing the levels of constitutively active Jak2 mutants. Epigenetic silencing of SOCS3 and SOCS1 was recently reported in about 40% of patients with Ph-negative chronic myeloid disorders

Structure/function: the potential interest of the Jak domains as drug targets
The domain structure of Jaks (MW: 120-140 kD) is shown in Figure 1 . Due to the lack of crystallographic data, the structure-function relationship of the interaction between cytokine receptors and Janus kinases still remains largely elusive as does the exact sequence of events involved in Janus kinase activation. Sequence similarities between Jak family members have led to the description of seven Jak homology (JH) domains [56] , which match the domain structure of Jaks only partially. Only the JH1 and JH2 domains correspond to the kinase and pseudokinase domain. The JH3 to JH7 regions are better described as a FERM and an SH2 domain [56, 57] .
Jak2
Pseudokinase 212, 213] C616Y ϩV617F (Exon14) ni ni PV / [214] V617F (Exon14) ϩ ϩ
PV, ET, PM, HES, CMML, SM, CNL, JMML, RARS, RA RCMD, RAEB, AML, IE, RARS-T, MDS/MPN-U, MPN-U
Jak1-V658 [25-29, 82, 208, 211, 215-221] C618RϩV617F (Exon14) ni ni PV CR: Jak3-A593 [222, 223] D620E (Exon14) ni ni PV, leukocytosis / [224, 225] ⌬exon15ϩ16 (⌬N622-D710) ni ni MDS/MPN-U / [226] I682F (Exon16) ϩ ϩ ch-B-ALL / [97] I682AQG (Exon16) ni ni DS-B-ALL / [97] R683G (Exon16) ϩ ϩ
DS-B-ALL, B-ALL
Jak1-R724 Jak3-R657 [97, 188, 227, 228] 97, 188, 227, 228] R683T (Exon16) ni ni DS-B-ALL Jak1-R724 Jak3-R657 [227] R683K (Exon16) ϩ ϩ DS-B-ALL Jak1-R724 Jak3-R657 [188] ⌬IREED ( ϭ I682 Table 1 ). However, because no structural data are yet available, the mechanism by which the pseudokinase domain inhibits the kinase can only be speculated about.
Interestingly, the Jak2-V617F mutation was described to be transferable to Jak1 and Tyk2 but not to Jak3 [96] . Later, the corresponding Jak1-V658F mutant was identified in ALL and AML patients [97, 98] . Similarly, transfer of the Jak3-A572V mutation to Jak2 does not lead to activation of Jak2 (C. Haan, unpublished data). Although it is too premature to be sure, there might be a difference in how Jak3 activity is inhibited by the pseudokinase domain compared to the three others. Table S1 summarizes the different cytokine families and the Jaks which are activated upon stimulation [7, [9] [10] [11] .
The pseudokinase domain as drug target
The recent discovery of more and more Jak mutations in disease has sparked the development of a host of low nanomolar inhibitors with different selectivity within the Jak family, and some compounds are tested in clinical trials [5, 13] [130] ). Interestingly, also long-term IFN-␣ treatment has been described to lead to complete and sustained molecular remission in patients with PV [131] [132] [133] . Because IFN-␣ signals via Jak1 and Tyk2, a specific Jak2 inhibitor might potentially be combined with IFN-␣ treatment to also achieve a reduction of the allele load. (Fig. 2) [174] . Using an inhibitor selective of the askinase as a reference compound in comparison with a novel drug candidate, it will be possible to clearly differentiate off-target effects from those elicited by the kinase in question. Moreover, these transgenic mice expressing an analogue-sensitive allele could be used to detect biomarkers associated with the activity and inhibition of a given kinase [175] . [170, 181] . [183] [184] [185] .
Mutant alleles encoding as-kinases have also been successfully introduced into mice [168-170]. Administration of bulky inhibitors (by intraperitoneal injection and/or by addition into the drinking water) indeed allowed the assignment of novel in vivo functions, in particular to the BDNF receptor TrkB [168, 171-173]. Such in vivo model systems can also be very valuable for pharmacologically relevant target validation
Identification of direct substrates
Structure-based interpretation of the Jak mutations
With a rapidly growing number of Janus kinase mutations that are reported it is tempting to speculate about their impact on the molecular events that favour disease development and/or progression. An obvious way to approach this is to bring structural considerations into the game. For the Jaks, this is facilitated by the availability of solved crystal structures of the kinase domains of Jak1, Jak2 and Jak3. Furthermore, molecular modelling approaches allow to rather accurately predict the location of amino acid residues in protein domains that show a high degree of conservation. However, the prediction of the molecular effects of specific mutations requires biochemical information about the activation status of the respective mutant Janus kinase. Here we provide an overview of the Jak mutations that have been reported in the context of haematologic diseases (
Mutations within the FERM and SH2 domains
Various mutations within the FERM and SH2 domains of Jak1, Jak3 and Tyk2 were described to be associated with haematologic diseases (Fig. S4 and Table 1 Figure S4 can only provide information about the location of highly conserved and structurally important residues. As the alignment in Figure S3 shows [186] .
) but only for I87T and P132T in the FERM domain of Jak3 as well as for T478S within the SH2 domain of Jak1 biochemical data have been gathered. Due to the divergent nature of the Janus kinase FERM domain in comparison to other FERM domains, molecular models such as the one presented in
, these mutations mostly affect residues which are not well conserved between the Jaks and the sequences of other FERM domains. Thus, the information provided by the model structure remains very hypothetical, especially concerning the location of the residues K204, R360 in Jak1 and P151R in Jak2. The accuracy of the predicted location of I62, P132 and I87 is more reliable. Our model structure of the Jak3 FERM domain suggests that P132 and I87 could be involved in the positioning of the alpha helix in the F1 subdomain by contacting residues at both ends of the helix (L49 for P132/G63 and L64 for I87). As mutation of both P132 and I87 has been shown to lead to constitutive activity of the kinase, one could speculate that the region around the F1 ␣-helix is involved in the regulation of kinase activity. Interestingly, a mutation within the corresponding helix in Jak1, I62V, was also reported, but unfortunately not further characterized
The effect of the reported mutations within the SH2 domain of Jak1 and Jak3 is hard to predict as two of the mutations are located in loop regions (S512 in the EF-loop of Jak1 and P434 in the DE-loop of Jak3). However, in principle both S512 and P434 are located in interesting regions within the SH2 domain as the EFloop participates in the recognition of phosphotyrosine motifs in SH2 domains and the DE-loop of the N-terminal SH2 domain of SHP2 was shown to inhibit the phosphatase activity of this enzyme [187]. The reported activating effect of the T478S mutation in Jak1 is also not that obvious. Although this residue is usually involved in the formation of a hydrogen bond network around the phosphate group of a bound phosphotyrosine residue, an exchange to serine should not impair that function. In fact, most SH2 domains contain a serine residue at this position (serine residue in ~50% and threonine in ~25% of SH2 domains (see also Fig. S3). Rather than directly affecting a potential interaction with a phosphotyrosine motif, the T478S mutant may partially destabilize the SH2 domain and could thereby affect interdomain interactions in a way that leads to constitutive signalling.
Mutations within the kinase-like domain
The alignment of the pseudokinase domains (Fig. S3) Figure 3 Fig. 3 ) and exert their effects via a similar molecular mechanism. For example, the exon 12-encoded residue K539 (which seems to be a key residue in exon 12) and the amino acid V617 are in close proximity (Fig. 3) 97, 186, 188, 190, 191] and references [40, 192, 193] which use previously generated model structures of Lindauer et al. [190] and Giordanetto et al. [192] [101, 102] ). In such a conformation, the A-loop would cross the catalytic cleft, the regulatory ␣C-helix would be rotated and the relative orientation between the two lobes of the pseudokinase domain would change. In addition, the models which were used to develop the potential inhibitory mechanism are not based on the later described crystal structures of the Jak kinase domains. It would be interesting to incorporate the solved structures of Jak1, Jak2 and Jak3 and their special features such as the Lip/JSI-region into these interaction models. However, the solved kinase domain structures are also not optimal because they reflect the activated states of the kinases with an 'out'-conformation of the A-loop and all its consequences for the structure. As described above, there may be important differences between the inactive A-loop conformations of Jak3 compared to the other Jaks due to the alanine residue preceding the DGF-motif. On the other hand, the conformation of the activated A-loops of Jak1, Jak2 and Jak3 seen in the crystal structures are almost identical (see Fig. S7 ). The potential difference in the inactive state could suggest a different inhibitory interface between the kinase and pseudokinase domains in the case of Jak3. Most interestingly, such a theory would be in line with experimental data as it was reported that the Jak3 M592F mutation, which corresponds to the Jak2-V617F mutation does not activate Jak3 whereas corresponding mutations in Jak1 and Tyk2 are activating [96] . Of course, this theory remains speculative and only crystal structures of the different Jaks encompassing at least the pseudokinase and kinase domains will provide definite proof for these regulatory mechanisms.
shows a model structure of the Jak2 pseudokinase domain with the positions of the biochemically validated activating mutations (please refer to Figure S5 for a representation of validated activating pseudokinase mutants for all the Jak family members and to Figure S6 for all identified pseudokinase mutations in the Jaks). Based on our model structures, we hypothesize that the activating exon 12 mutations (referring to Jak2) and the mutations between the ␤3 and ␤5 strands (e.g. the Jak2-V617F and most other Jak2 exon 14 mutations) belong to the same structural hotspot (structural hotspot I in
Mutations within the kinase domain
In comparison to the kinase-like domain, far less activating mutations have been described for the kinase domain. Mutational hotspots are well known in protein kinases and they are often kinase domain mutations. One example is the V600 mutation within the A-loop in BRAF [194] which generates an active kinase. The mutation of the corresponding residue is also found in MET, FLT3 and KIT [195] [196] [197] [198] [199] [200] . However, the mutations in the Jak kinase domain are rare events compared to the occurrence of mutations in the pseudokinase domain.
Most mutations are confined to a loop-region between the ␤2 and ␤3 strands of Jak2 (R867Q, D873N, T875N) (Fig. S7) . Similarly, the other reported mutations (P933R in Jak2 and R879C/H/S in Jak1) affect residues which are exposed on the surface and do not affect the structure of the domain. Considering the kinase-pseudokinase interaction model by Lindauer and colleagues [190] , none of the activating Jak2 mutations can be attributed to the proposed interface between the two domains. [98] , and since Jaks would be potentially interesting targets in inflammatory disorders, the interest in developing specific Jak inhibitors will surely increase.
Perspectives
Further insights into the structure of Janus kinases, ideally solved structures of domain combinations, will certainly give answers to questions currently still open: How do the domains interact with each other and with the cytokine receptor? Which structural changes are imposed on Jaks during activation of the cytokine receptor complex? How do the disease-associated mutations in Jaks translate into a gain-of-function phenotype? What is the molecular basis of the mutational hotspots associated with either MPN or leukaemia? Moreover, also proteomic analyses of the Jakassociated proteins will provide insights into the nature of the signalling complexes engaged by the different mutants and the wildtype kinases. As more and more Jak mutations are discovered in haematopoietic disorders and also in solid tumours
The 
of the Jak2 pseudokinase domain (amino acids 540-810). For the modelling of the activation loop region (aa R688-R715 in Jak2) in an "in"-conformation, the conformation of the inactive activation loop of the insulin receptor (IR; aa T1145-P1172 ; PDB entry code 1IRK) was chosen as a template. The modelling of the Exon12 amino acids 533-539 of Jak2 was based on the N-terminal region of the EGFR kinase domain structure (aa 700-706; PDB code 2GS6). Energy minimizations were performed under vacuum conditions with the GROMOS program library (W. F. van Gunsteren, distributed by BIOMOS
